ASTRABIO

Starting with precision and Striving for health

Scroll down

01 /
Suzhou ASTRABIO Co., Ltd.

About us

Starting with precision and Striving for health

Suzhou Astrabio is a high-tech and leading company in China that achieved the industrialization of single molecule immune-detection of for both clinical diagnosis and translational biomarker application with its fully owned lP. The company is located in Building 14,Liandong U Valley, Suzhou industrial Park,and has nearly 8,000 square meters of R&D and production center. Meanwhile, the company also revived serval round of investment from local leading VC and MNC funding.
The company always adheres to the innovative concept of "Starting with precision and Striving for health", and committed to the research and industrialization of the next generation of single molecule immuno diagnostic technology.

Vision: To be a trusted supporter and leader for customers in life and health field.

  • T

    Technica

    Independent intellectual property rights
  • R

    R&D adva

    Top R&D team
    Nearly 100 kinds of kits
  • Q

    Quality

    8000㎡ production center Clinical level command system

Homebrew Reagent Customization Service

01

Project initiation

Key indicators input
  • Development purpose
  • Development focus
  • Assessment indicators
  • Technical requirements
  • Output
02

Biomarker Discover

Proteomic assays
  • Marker Screening

  • Sample detection

  • Data analysis

03

Raw material development

Antibodies preparati
  • Antibodies preparation

  • Antibodies preparation&assessment

  • Paired antibody assessment

04

Single molecule kits development

Bio-labeling, reagen
  • Magnetic bead screening

  • Buffer system

  • Anti-interference system

  • Concentration optimization

05

Kit performance assessment and validatio

Output of test resul
  • Sensitivity

  • Specificity

  • Detection range

  • Anti-interference ability

  • Stability

  • Registration for use

06

Clinical transformation and application

Clinical sample vali

Flexible application

Alzheimer's disease online risk assessment platform
Accumulated detection4523sample size